NEO (NeoGenomics) Total Stockholders Equity: $785.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEO NeoGenomics Inc NEO
75 GF Score
Price $16.58
GF Value $16.00
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Total Stockholders Equity?

NeoGenomics NEO +6.56% 75 Total Stockholders Equity is $785.7 Mil as of Jun. 2026. GuruFocus rates NEO with a GF Score™ of 75/100 and a GF Value™ of $16.00 (Fairly Valued). The stock has 6 warning signs investors should review.

NeoGenomics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $785.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NeoGenomics's Book Value per Share for the quarter that ended in Jun. 2026 was $6.14. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NeoGenomics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.57.

NeoGenomics  (NAS:NEO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NeoGenomics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(785.732-0)/127.918
=6.14

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NeoGenomics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.426 + 442.942) / 785.732
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Total Stockholders Equity Related Terms

NeoGenomics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Total Stockholders Equity Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,108.28 998.02 941.54 902.34 836.56

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 854.04 838.29 836.56 828.76 785.73
NEO
75GF Score
NeoGenomics Inc NEO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $785.7 Mil mean?
NeoGenomics (NEO) has a Total Stockholders Equity of $785.7 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Total Stockholders Equity too high?
NeoGenomics' current Total Stockholders Equity is $785.7 Mil. Overall, NeoGenomics has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Stockholders Equity compare to WGS and CDNA?
NeoGenomics' Total Stockholders Equity of $785.7 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors. NeoGenomics's current Total Stockholders Equity is $785.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Fairly Valued. The stock's GF Value™ is $16.00, compared to a current price of $16.58 — trading 3.6% above its estimated fair value. The current Total Stockholders Equity is $785.7 Mil. NeoGenomics' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For NeoGenomics (NEO), the current Total Stockholders Equity is $785.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be overvalued. The current stock price of $16.58 is trading 3.6% above its estimated GF Value™ of $16.00. GuruFocus considers NeoGenomics to be Fairly Valued.

Key valuation signals for NEO:

  • Total Stockholders Equity: $785.7 Mil
  • GF Value™: $16.00 vs. price of $16.58 (3.6% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
75GF Score

Get the complete analysis for NEO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.58
Price
$16.00
GF Value